Merck's Oral PCSK9 Inhibitor Shows Promising Results in Phase 3 Trials
TL;DR Summary
Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, with no major safety concerns, potentially making it the first oral PCSK9 inhibitor if approved.
- Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia Business Wire
- Merck's potential blockbuster cholesterol pill succeeds in late-stage studies Reuters
- Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials Fierce Biotech
- Merck & Co.'s oral PCSK9 inhibitor succeeds in dual Phase III trials FirstWord Pharma
- Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point. Barron's
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
7 min
vs 8 min read
Condensed
97%
1,517 → 40 words
Want the full story? Read the original article
Read on Business Wire